Mark Stein, PhD, ABPP

Personal Statement

I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to  our behavioral group treatment programs and treatment recommendations.   The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves  diagnostic evaluations and consultations  for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for  individuals with ADHD.    I have  assisted in the development of several stimulant  and non stimulant medications, and participated in many clinical trials. Currently, we are   conducting a study  for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication  and  behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD,  and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.

Education

Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago

Department Affiliations

Other Affiliations

PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic

 

Center for Child Health, Behavior, and Development

 

Brotman Baty Institute

Recent Publications

A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder.
(2026 Jul 17)
J Urol
DeCastro GJ, Joffe BI, Stein MN, Abate-Shen C, Miles CH, Gray JM, Anderson CB, Lenis AT, McKiernan JM

Targeting human kallikrein 2 in prostate cancer.
(2026 Jun)
Clin Adv Hematol Oncol 24(4): 230-231
Stein MN

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.
(2026 May 18)
Clin Cancer Res
El Ahmar N, Paul MA, Simsek B, Matar S, Jegede OA, Laimon YN, Savla V, Mohanna R, de Oliveira GR, Bagheri Sheshdeh A, Denize T, West DJ, Seager MD, Sun M, Choueiri TK, Xie W, Freeman GJ, Sharpe AH, Braun DA, Haas NB, Hammers H, Bilen MA, Stein M, Sosman JA, Wu CJ, McDermott DF, Atkins MB, Signoretti S

Treatments on the Horizon for Men with Advanced Prostate Cancer.
(2026 May)
Urol Clin North Am 53(2): 331-342
Ehrlich MI, Gejman RS, Bernstein E, Stein MN

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.
(2026 Mar 17)
Cell Rep Med 7(3): 102638
Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, Shah P, Pan SS, Laplaca CJ, Virk RK, Hill JC, Jugler C, DeFranco G, Bhattacharya N, Copple KR, Nguyen P, Scher HI, DeCastro GJ, Anderson CB, McKiernan JM, Spina CS, Stein MN, Runcie K, Drake CG, Califano A, Dallos MC

Show complete publication list »
Edit Profile